Ignite Creation Date:
2025-12-24 @ 10:20 PM
Ignite Modification Date:
2025-12-25 @ 7:53 PM
Study NCT ID:
NCT00421135
Status:
COMPLETED
Last Update Posted:
2009-09-17
First Post:
2007-01-10
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer
Sponsor:
Alaunos Therapeutics
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
IPM1001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Jonathan Lewis, MD PhD Chief Medical Officer
Old Organization:
ZIOPHARM Oncology, Inc